CONMED (CNMD) Stock Forecast & Price Target

Conmed Corp has demonstrated strong growth in its high-demand product segments, particularly with the BioBrace rotator cuff repair device, which is set for a full release in the third quarter of 2025 following its FDA approval. Despite facing supply constraints, the Foot & Ankle segment also achieved double-digit growth, indicating resilience and potential easing of supply chain issues. Moreover, the company's conservative revenue guidance reflects an ongoing commitment to improving top-line performance, suggesting optimistic prospects for revenue growth in the latter half of the year.

Conmed Corp is experiencing a significant decline in its stock price, with shares down approximately 27% year-to-date, indicating challenges in executing its turnaround strategy. The company's recent capital weakness, particularly in international markets, is primarily linked to challenging year-over-year comparisons rather than a broader slowdown in hospital capital budgets. Furthermore, the revision of the price target from $80 to $68 reflects a growing concern over Conmed's financial performance, as it is now based on a forward price-to-earnings ratio of around 15x the estimated FY'25 earnings per share of $4.46.